Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Changes to Physician Assistant Statutes in Florida

Client Alert

In the last year, there have been many changes to the scope of practice and collaboration/supervision requirements for advanced practice providers such as APRNs and physician assistants in the state of Florida.  In a previous Client Alert we discussed House Bill 607, which expanded the autonomous practice of APRNs providing primary care services in Florida.

This Client Alert focuses on Florida House Bill 431 (the “Bill”), which went into effect on July 1, 2021 and amended Florida Statutes 458.347 and 459.022. The Bill essentially gives Florida PAs more autonomy in certain aspects of their practice, and changes the number of PAs that physicians are permitted to supervise from four (4) to ten (10).

The Florida Board of Medicine published the comprehensive list of all of the changes made, and among those, PAs are no longer required to notify patients that they have the right to see a physician before prescribing or dispensing prescriptions, and they are able to authenticate any document that may also be authenticated by physicians, with the exception of physician certifications (which includes, but is not limited to, death certificates, school physical exams, and medical examinations for workers’ compensation claims).

Additionally, PAs are no longer required to notify the Department of Health in writing when any changes are made to their supervising physician or within thirty (30) days of employment, and are permitted to supervise medical assistants.

As for changes in prescribing, PAs no longer need to include a prescribing number on prescriptions, but instead must include their name, address, and phone number, along with the name of each of their supervising physicians. Additionally, a formulary that lists prescriptions PAs are not allowed to prescribe will be published, and PAs can now prescribe 14-day supplies of Schedule II psychotropic drugs to minors, provided they are supervised by a pediatrician, family practice physician, internal medicine physician, or psychiatrist.

The Board of Medicine also noted the following changes from the Bill:

  • Amends provisions related to program approval for the education and training of PAs and allows trainees to perform medical services rendered within the scope of an approved program;
  • Amends the licensure requirements for PAs based on the date a PA graduated from an approved program as defined in the bill by specifying which PA education and training programs are approved for PA licensure;
  • Authorizes a PA to satisfy the continuing education requirement on controlled substance prescribing through a designated course; and
  • Removes the requirement that PA licensure applicants seeking prescribing authority provide course transcripts.

If you have any questions about any of the specific changes or additions to Florida Statutes 458.347 and 459.022, and how they are applicable to you and your practice, please contact Amanda Waesch at alwaesch@bmdllc.com.


Ohio Board of Pharmacy Update: Key Regulatory Changes and Proposals You Need to Know

The Ohio Board of Pharmacy (BOP) has rescinded certain OAC rules (OAC 4729:5-18-01 through 4729:5-18-06), removing regulations on office-based opioid treatment (OBOT) clinics. The rescissions took effect on June 3, 2024. The BOP also published a new rule, OAC 4729:8-5-01, which sets explicit reporting guidelines for licensed dispensaries and became effective on June 7, 2024.

LGBTQIA+ Patients and Discrimination in Healthcare

In early April, the Kaiser Family Foundation released a study outlining the challenges that LGBT adults face in the United States related to healthcare. According to the study, LGBT patients are “twice as likely as non-LGBT adults to report negative experiences while receiving health care in the last three years, including being treated unfairly or with disrespect (33% v. 15%) or having at least one of several other negative experiences with a provider (61% v. 31%), including a provider assuming something about them without asking, suggesting they were personally to blame for a health problem, ignoring a direct request or question, or refusing to prescribe needed pain medication.”

Ohio Recovery Housing Overhaul: New Standards and Certification Requirements Reshape Sober Living Spaces

Ensuring Fair Access: SB 269 Protects Affordable Medication for Low-Income Patients

SB 269, introduced on December 19, 2023, will ensure that 340B covered entities, including Federally Qualified Health Centers, Ryan White Clinics, disproportionate share hospitals, and Title X clinics, can acquire 340B drugs without facing undue restrictions or discriminatory practices from drug manufacturers and distributors. This protection is crucial for 340B covered entities to continue to provide affordable medications and comprehensive services to low-income patients.

Unveiling Ohio's Pharmacy Board Updates for Distributors, Mobile Clinics, and Controlled Substances

The Ohio Board of Pharmacy will hold a public hearing on May 28, 2024, to discuss several proposed changes and additions to Ohio Administrative Code (OAC). These changes pertain to terminal distributors of dangerous drugs (TDDDs), mobile clinics or medication units, and the classification of controlled substances.